stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.58
1.45
−5.57%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) P/S ratio
As of 5 November 2026, Caris Life Sciences,�Inc. (CAI) trades at a P/S ratio of 7.1×. Over the past ten years it has ranged from 0.0× (June 2025) to 15.0× (October 2025); the current reading is higher than 58% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 9.4× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 8.3× | 62.87% |
| Jun 2026 | 5.1× | (8.52%) |
| Mar 2026 | 5.6× | (40.61%) |
| Dec 2025 | 9.4× | (31.79%) |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 15.0×
Ten-year median
6.5×
Current reading's percentile
58
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| CAI Caris Life Sciences,�Inc. | 7.1× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 8.2× |
| TGTX TG Therapeutics, Inc. compare | 10.3× |
| TWST Twist Bioscience Corporation compare | 17.6× |
| KRYS Krystal Biotech, Inc. compare | 18.9× |
| PTGX Protagonist Therapeutics, Inc. compare | 31.7× |
| IBRX ImmunityBio, Inc. compare | 51.0× |
| CYTK Cytokinetics, Incorporated compare | 64.4× |
| SYRE Spyre Therapeutics, Inc. compare | 8,160× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement